SCHEMBL3217535

SCHEMBL3217535

CN1CCN(Cc2ccc3[nH]ccc3c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K11 Q16584 2/20 0.56
MAPK14 Q16539 2/20 0.56
ROCK2 O75116 2/20 0.56
SGK1 O00141 1/20 0.56
IKBKB O14920 1/20 0.56
AURKA O14965 1/20 0.56
CHUK O15111 1/20 0.56
PRKAB2 O43741 1/20 0.56
ABL1 P00519 1/20 0.56
NTRK1 P04629 1/20 0.56
INSR P06213 1/20 0.56
LCK P06239 1/20 0.56
CDK1 P06493 1/20 0.56
IGF1R P08069 1/20 0.56
MET P08581 1/20 0.56
CYP3A4 P08684 1/20 0.56
SRC P12931 1/20 0.56
FLT1 P17948 1/20 0.56
CDK2 P24941 1/20 0.56
MAPK1 P28482 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27758936 0.98 MAP3K11 (0.55) MAP3K11MAPK14ROCK2SGK1IKBKB
SCHEMBL3047278 0.85 PKM (0.61) MAP3K11MAPK14ROCK2SGK1IKBKB
SCHEMBL3697284 0.85 MAPK14 (0.55) MAP3K11MAPK14ROCK2SGK1IKBKB
SCHEMBL13293706 0.84 FAAH (0.55) MAPK14ROCK2FAAHHTR1AHTR1D
SCHEMBL20752055 0.83 MAP3K11 (0.56) MAP3K11MAPK14FAAHHTR1AHTR1D
SCHEMBL5751064 0.82 FAAH (0.54) MAP3K11MAPK14ROCK2SGK1IKBKB
SCHEMBL18941210 0.82 FAAH (0.63) MAPK14FAAHHTR1AHTR1DHTR1B
SCHEMBL3695011 0.81 CHKA (0.53) MAP3K11MAPK14ROCK2SGK1IKBKB
SCHEMBL5751758 0.81 DRD4 (0.56) MAP3K11MAPK14KCNH2FAAHHTR1A
SCHEMBL26134148 0.81 FAAH (0.55) MAPK14ROCK2KCNH2FAAHDRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101544592-B Process for preparation of N-arylsulfonyl-3-substituted indoles SUVEN LIFE SCIENCES LTD 2013-08-21 CN disclosed
US-8470830-B2 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2013-06-25 US disclosed
CN-101553467-B 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LTD. (IN) 2011-12-07 CN disclosed
EP-2114878-B1 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LTD (IN) 2010-12-15 EP disclosed
US-20100041673-A1 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-02-18 US disclosed
EP-2114878-A1 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS Suven Life Sciences Limited (IN) 2009-11-11 EP disclosed
CN-101553467-A 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LTD (IN) 2009-10-07 CN disclosed
WO-2008084492-A1 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041673-A1 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS HTR6, HTR5A, HTR2C MAP3K11 2721/4885MAPK14 2038/4885ROCK2 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.